Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Xingyao Kunze Biomedical

Request full access

RNAi and antibody therapies for chronic liver diseases.

Suzhou Shi, ChinaFounded 2021Biotech & Life Sciences

About Xingyao Kunze Biomedical

Hepa Thera, legally known as Suzhou Xingyao Kunze Biopharmaceutical Co., Ltd., is a clinical-stage biotechnology company developing therapies for liver diseases, with a primary focus on achieving a functional cure for chronic hepatitis B (CHB). The company was established in May 2021 and is headquartered in Shanghai, China. It was incubated by Fosun Health Capital, following an innovation model inspired by Flagship Pioneering. On May 6, 2026, the company appointed Dr. Wu Kai as its Chief Executive Officer. In a significant financial development, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced on May 26, 2026, its intention to invest CNY 414 million to acquire a 20.87% stake in the company. Hepa Thera's core strategy centers on a dual-technology platform combining RNA interference (RNAi) and monoclonal antibodies to create effective combination therapies. The company's lead product pipeline targets chronic hepatitis B, a major global health issue affecting over 300 million people worldwide. Its main drug candidates are HT-101 and HT-102. HT-101 is a GalNAc-conjugated small interfering RNA (siRNA) designed to specifically silence hepatitis B viral transcripts, essentially stopping the production of viral proteins at the source. HT-102 is a neutralizing monoclonal antibody that clears circulating viral proteins, which helps restore the body's own immune control over the virus. This combination therapy has shown promising results in clinical trials, with a Phase 2 study demonstrating a 79% clearance rate of the hepatitis B surface antigen (HBsAg) at 24 weeks. The company is in the clinical trial stage of development and does not yet have commercial revenue. Its drug candidate HT-101 received Breakthrough Therapy Designation from China's Center for Drug Evaluation (CDE) as a monotherapy. The combination of HT-101 and HT-102 also received this designation from the NMPA. Furthermore, the U.S. FDA has cleared the initiation of Phase II clinical trials for the combination therapy. Beyond hepatitis B, Hepa Thera's pipeline extends to other unmet needs in liver disease, including hepatitis D, MASH (Metabolic dysfunction-associated steatohepatitis), and liver fibrosis, utilizing technologies such as fusion proteins and mRNA-based immunotherapy.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
19.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Drug Development, Genetics and genomics, RNA
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing May 2026 $54M $294M Tahoe Venture · Humble Capital · TG Sino-Dragon Fund · Jiaxing Deshi Private Equity Fund Management ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Xingyao Kunze Biomedical website traffic

Latest recorded traffic for Xingyao Kunze Biomedical is 450 monthly website visits.

Latest monthly visits450
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Xingyao Kunze Biomedical in the Suzhou Shi ecosystem

Live from Dealroom

The Xingyao Kunze Biomedical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A7 investors entered at this stage

  • Tahoe Venture
  • Humble Capital
  • TG Sino-Dragon Fund
  • Jiaxing Deshi Private Equity Fund Management
  • Shanghai Fosun Pharmaceutical
  • Kaitai Capital
  • Huajin Capital
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Suzhou Shi HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Xingyao Kunze Biomedical on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Xingyao Kunze Biomedical’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.